Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients

Research output: Contribution to conferenceConference abstract for conferenceResearch

Harvard

APA

Ebdrup, B. H., Knop, F. K., Madsen, A., Mortensen, H. B., Søgaard, B., Holst, J. J., ... Lublin, H. H. (2014). Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients. Abstract from Forskningsdag 2014, Glostrup Hospital, Glostrup, Denmark.

CBE

Ebdrup BH, Knop FK, Madsen A, Mortensen HB, Søgaard B, Holst JJ, Szecsi PB, Lublin HH. 2014. Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients. Abstract from Forskningsdag 2014, Glostrup Hospital, Glostrup, Denmark.

MLA

Vancouver

Ebdrup BH, Knop FK, Madsen A, Mortensen HB, Søgaard B, Holst JJ et al. Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients. 2014. Abstract from Forskningsdag 2014, Glostrup Hospital, Glostrup, Denmark.

Author

Ebdrup, Bjørn Hylsebeck ; Knop, Filip Krag ; Madsen, Anna ; Mortensen, Henrik Bindesbøl ; Søgaard, Birgitte ; Holst, Jens J ; Szecsi, Pal Bela ; Lublin, Henrik H. / Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients. Abstract from Forskningsdag 2014, Glostrup Hospital, Glostrup, Denmark.1 p.

Bibtex

@conference{f7c0dc40296d4abe95008867e1f802d3,
title = "Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients",
abstract = "Background and aim: Treatment with antipsychotic drugs is widely associated with metabolic side-effects such as overweight and disturbed glucose metabolism, but the mechanism underlying these side-effects are unclear.Materials and methods: Fifty-one non-diabetic, antipsychotic-treated male patients ((mean standard deviation) age: 33.1±6.7 years; body mass index (BMI) 26.0±4.7 kg/m2; waist circumference: 95.8±13.2 cm; glycated hemoglobin (HbA1c): 5.7±0.3{\%}) and 93 age and waist circumference-matched healthy male controls (age: 33±7.3 years; BMI: 26.1±3.9 kg/m2; waist circumference: 94.6±11.9 cm; HbA1c: 5.7±0.3{\%}) participated in this cross-sectional study. Blood was sampled in the fasting state and 90 min. after ingestion of a standardized liquid meal (2.268 kJ). Results: Compared to healthy controls, patients were characterized by elevated fasting levels of glucose, proinsulin, C-peptide and glucose-dependent insulinotropic polypeptide (GIP) and higher postprandial levels of insulin, proinsulin, C-peptide and GIP. Also, patients exhibited elevated plasma levels of C-reactive protein and signs of dyslipidermia. Fasting plasma levels of insulin, glucagon, glucagon-like peptide-1 (GLP-1), ghrelin, leptin, adiponectin, tumor necrosis factor-alpha, plasminogen activator inhibitor, interleukin 6 and postprandial levels of glucagon, GLP-1, ghrelin and adiponectin did not differ between groups. Conclusion: Presenting with an insulin resistant-like pattern, including beta cell hypersecretion and elevated GIP levels, non-diabetic antipsychotic-treated patients display emerging signs of dysmetabolism and a compromised cardiovascular risk profile. The appetite regulating hormones, GLP-1 and ghrelin appear not to be influenced by antipsychotic treatment. Our findings provide further clinical evidence of the metabolic side-effects of antipsychotics, and put emphasis on the importance of incorporating metabolic screening into psychiatric practice.",
author = "Ebdrup, {Bj{\o}rn Hylsebeck} and Knop, {Filip Krag} and Anna Madsen and Mortensen, {Henrik Bindesb{\o}l} and Birgitte S{\o}gaard and Holst, {Jens J} and Szecsi, {Pal Bela} and Lublin, {Henrik H.}",
year = "2014",
month = "10",
language = "English",
note = "null ; Conference date: 08-10-2014 Through 08-10-2014",

}

RIS

TY - ABST

T1 - Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients

AU - Ebdrup, Bjørn Hylsebeck

AU - Knop, Filip Krag

AU - Madsen, Anna

AU - Mortensen, Henrik Bindesbøl

AU - Søgaard, Birgitte

AU - Holst, Jens J

AU - Szecsi, Pal Bela

AU - Lublin, Henrik H.

PY - 2014/10

Y1 - 2014/10

N2 - Background and aim: Treatment with antipsychotic drugs is widely associated with metabolic side-effects such as overweight and disturbed glucose metabolism, but the mechanism underlying these side-effects are unclear.Materials and methods: Fifty-one non-diabetic, antipsychotic-treated male patients ((mean standard deviation) age: 33.1±6.7 years; body mass index (BMI) 26.0±4.7 kg/m2; waist circumference: 95.8±13.2 cm; glycated hemoglobin (HbA1c): 5.7±0.3%) and 93 age and waist circumference-matched healthy male controls (age: 33±7.3 years; BMI: 26.1±3.9 kg/m2; waist circumference: 94.6±11.9 cm; HbA1c: 5.7±0.3%) participated in this cross-sectional study. Blood was sampled in the fasting state and 90 min. after ingestion of a standardized liquid meal (2.268 kJ). Results: Compared to healthy controls, patients were characterized by elevated fasting levels of glucose, proinsulin, C-peptide and glucose-dependent insulinotropic polypeptide (GIP) and higher postprandial levels of insulin, proinsulin, C-peptide and GIP. Also, patients exhibited elevated plasma levels of C-reactive protein and signs of dyslipidermia. Fasting plasma levels of insulin, glucagon, glucagon-like peptide-1 (GLP-1), ghrelin, leptin, adiponectin, tumor necrosis factor-alpha, plasminogen activator inhibitor, interleukin 6 and postprandial levels of glucagon, GLP-1, ghrelin and adiponectin did not differ between groups. Conclusion: Presenting with an insulin resistant-like pattern, including beta cell hypersecretion and elevated GIP levels, non-diabetic antipsychotic-treated patients display emerging signs of dysmetabolism and a compromised cardiovascular risk profile. The appetite regulating hormones, GLP-1 and ghrelin appear not to be influenced by antipsychotic treatment. Our findings provide further clinical evidence of the metabolic side-effects of antipsychotics, and put emphasis on the importance of incorporating metabolic screening into psychiatric practice.

AB - Background and aim: Treatment with antipsychotic drugs is widely associated with metabolic side-effects such as overweight and disturbed glucose metabolism, but the mechanism underlying these side-effects are unclear.Materials and methods: Fifty-one non-diabetic, antipsychotic-treated male patients ((mean standard deviation) age: 33.1±6.7 years; body mass index (BMI) 26.0±4.7 kg/m2; waist circumference: 95.8±13.2 cm; glycated hemoglobin (HbA1c): 5.7±0.3%) and 93 age and waist circumference-matched healthy male controls (age: 33±7.3 years; BMI: 26.1±3.9 kg/m2; waist circumference: 94.6±11.9 cm; HbA1c: 5.7±0.3%) participated in this cross-sectional study. Blood was sampled in the fasting state and 90 min. after ingestion of a standardized liquid meal (2.268 kJ). Results: Compared to healthy controls, patients were characterized by elevated fasting levels of glucose, proinsulin, C-peptide and glucose-dependent insulinotropic polypeptide (GIP) and higher postprandial levels of insulin, proinsulin, C-peptide and GIP. Also, patients exhibited elevated plasma levels of C-reactive protein and signs of dyslipidermia. Fasting plasma levels of insulin, glucagon, glucagon-like peptide-1 (GLP-1), ghrelin, leptin, adiponectin, tumor necrosis factor-alpha, plasminogen activator inhibitor, interleukin 6 and postprandial levels of glucagon, GLP-1, ghrelin and adiponectin did not differ between groups. Conclusion: Presenting with an insulin resistant-like pattern, including beta cell hypersecretion and elevated GIP levels, non-diabetic antipsychotic-treated patients display emerging signs of dysmetabolism and a compromised cardiovascular risk profile. The appetite regulating hormones, GLP-1 and ghrelin appear not to be influenced by antipsychotic treatment. Our findings provide further clinical evidence of the metabolic side-effects of antipsychotics, and put emphasis on the importance of incorporating metabolic screening into psychiatric practice.

M3 - Conference abstract for conference

ER -

ID: 44614487